Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.
Non-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.
Data from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.
Median TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).
Lower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up.
This is a preview of subscription content,to check access.
Access this article
U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD
Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501
Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951
Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216
Pickney CS, Arnason JA (2005) Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16:1156–1160
Burgener M, Arnold M, Katz JN, Polinski JM, Cabral D, Avorn J, Solomon DH (2005) Older adults’ knowledge and beliefs about osteoporosis: results of semistructured interviews used for the development of educational materials. J Rheumatol 32:673–677
Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921
Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259–262
Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886
Kendler D, Kung AW, Gel-H F, González González JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243–251
Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shaloms S (2005) Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 17:143–149
Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861
Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43–49
Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2–S6
Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205–210
Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383–2391
Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM (2006) An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 90:217–221
Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644
Shikiar R, Rentz AM (2004) Satisfaction with medication: an overview of conceptual, methodological, and regulatory issues. Value Health 7:204–215
Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA (2009) Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J 102:486–492
Barrett-Connor E, Ensrud K, Tosteson ANA, Varon SF, Anthony M, Daizadeh N, Wade S (2009) Design of the POSSIBLE USTM Study: postmenopausal women’s compliance and persistence with osteoporosis medications. Osteoporos Int 20:463–472
Tosteson ANA, Do T, Wade S, Anthony M, Downs R (2010) Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™. Osteoporos Int 21:1769–1780
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12
Centers for Disease Control and Prevention. About BMI for Adults. http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html 7/27/09. Accessed 6 September 2010
Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456
McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23(12):3137–3152
Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23(11):1815–1821
Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Pyschomatic Res 47(6):555–567
Horne R, Weinman J (2002) Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatments beliefs in explaining non-adherence to preventer medication. Psychol Health 17:17–32
Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K (2003) Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt) 12:1037–1045
Pencille LJ, Campbell ME, Van Houten HK, Shah ND, Mullan RJ, Swiglo BA, Breslin M, Kesman RL, Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Wermers RA, Melton LJ 3rd, Montori VM (2009) Protocol for osteoporosis choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials 10:113
Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R (2009) Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) 18:935–943
Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized crossover study (BALTO II). Joint Bone Spine 75:303–310
Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903
Payer J, Killinger Z, Sulková I, Celec P (2008) Preferences of patients receiving bisphosphonates—how to influence the therapeutic adherence. Biomed Pharmacother 62:122–124
Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, Borenstein J, Wang H, Man HS, Wagman RB, Siddhanti S, Macarios D, Bone HG (2010) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837–846
Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20(12):2127–2134
The authors would like to acknowledge the other members of the POSSIBLE US™ Steering Committee: Robert Downs, Ted Ganiats, Marc Hochberg, Barbara Lukert, Robert Recker, Robert Rubin and Anna Tosteson. We would also like to acknowledge the REGISTRAT, Inc. staff members who assisted with the implementation of this study and ongoing data collection, as well as Sue Hudson, who provided editorial assistance on behalf of Amgen Inc. Funding for this study was provided by Amgen Inc., Thousand Oaks, CA USA.
Conflicts of interest
E. Barrett-Connor receives support from Amgen, Inc. for serving as Chair of the POSSIBLE US™ Study Steering Committee; she is an investigator on clinical trials for Arena Pharmaceuticals, Boehringer Ingelheim, Merck, Pfizer and Roche. Dr. Barrett-Connor also receives grant funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources (NCRR), and NIH Roadmap for Medical Research. S. Wade and S. Satram-Hoang provide consulting services to Amgen Inc. T. P. Do, R. Stewart, G. Gao, and D. Macarios are employees of Amgen Inc. and have received Amgen stock/stock options.
About this article
Cite this article
Barrett-Connor, E., Wade, S.W., Do, T.P. et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporos Int 23, 733–741 (2012). https://doi.org/10.1007/s00198-011-1620-3